Cosentyx (secukinumab) prior authorization denied appeal
IL-17A inhibitor for PsO, PsA, AS, nr-axSpA, HS, ERA, JPsA
Typical PA criteria
- Approved indication with ICD-10
- Prior conventional therapy or DMARD trial
- Specialist prescriber
- TB/HBV screening
Why your PA was denied
- Preferred biosimilar or biologic not tried
- Prior systemic/DMARD trial not documented
- IBD history flag (Cosentyx not preferred with IBD)
- Screening absent
Evidence that overturns the denial
- ✓PASI, BSA, DAS28, or BASDAI at baseline
- ✓Prior systemic therapy dates, doses, outcomes
- ✓Specialist letter
- ✓TB/HBV negative screening
Avoid Cosentyx in patients with active or history of IBD — TNF inhibitors or IL-23s are preferred if IBD is comorbid.
Free analysis identifies the cited policy and missing evidence. Then a finished letter that maps your chart to the criteria.
FAQ
Why was my Cosentyx (secukinumab) prior authorization denied?+
The most common reasons are: Preferred biosimilar or biologic not tried; Prior systemic/DMARD trial not documented; IBD history flag (Cosentyx not preferred with IBD). Your denial letter names the specific criteria you did not meet.
How do I appeal a Cosentyx (secukinumab) denial?+
File a written appeal within 180 days that cites the insurer's clinical policy, includes a letter of medical necessity from the prescriber, and documents the criteria the insurer requires.
What evidence overturns a Cosentyx (secukinumab) denial?+
PASI, BSA, DAS28, or BASDAI at baseline; Prior systemic therapy dates, doses, outcomes; Specialist letter.
What if the plan excludes Cosentyx (secukinumab) entirely?+
Plan exclusions are different from medical-necessity denials. Check the Summary Plan Description. If the drug is fully excluded, an appeal will not overturn it; you may need a formulary exception or manufacturer assistance program.
Other drugs
- Wegovy (semaglutide)
- Zepbound (tirzepatide)
- Ozempic (semaglutide)
- Mounjaro (tirzepatide)
- Saxenda (liraglutide)